Back to Search
DR. MARWAN ABDELRAHIM M.D.
M.D.
Internal Medicine Physician
NPI: 1538693650IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
ME170381(FL)
Education
OTHER
Class of 2014
Research & Publications (20)
Aerodynamic characteristics of nebulized terbutaline sulphate using the Next Generation Impactor (NGI) and CEN method.
PMID 19392586·J Aerosol Med Pulm Drug Deliv·2009
8-other
Stanniocalcin-1 suppresses superoxide generation in macrophages through induction of mitochondrial UCP2.
PMID 19602668·J Leukoc Biol·2009
7-preclinical
Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression.
PMID 19258429·Mol Cancer Ther·2009
7-preclinical
Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met.
PMID 19406933·Carcinogenesis·2009
7-preclinical
The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression.
PMID 19435870·Mol Cancer Ther·2009
7-preclinical
Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells.
PMID 19582879·Int J Cancer·2009
7-preclinical
1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through activation of c-jun N-terminal kinase.
PMID 18460448·Carcinogenesis·2008
7-preclinical
5,5'-Dibromo-bis(3'-indolyl)methane induces Kruppel-like factor 4 and p21 in colon cancer cells.
PMID 18645021·Mol Cancer Ther·2008
7-preclinical
Structure-dependent activation of endoplasmic reticulum stress-mediated apoptosis in pancreatic cancer by 1,1-bis(3'-indoly)-1-(p-substituted phenyl)methanes.
PMID 18852139·Mol Cancer Ther·2008
8-other
Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins.
PMID 18006642·Mol Endocrinol·2008
8-other
1,1-bis(3'-indolyl)-1-(p-methoxyphenyl)methane activates Nur77-independent proapoptotic responses in colon cancer cells.
PMID 17957723·Mol Carcinog·2008
8-other
1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes induce apoptosis and inhibit renal cell carcinoma growth.
PMID 18006776·Clin Cancer Res·2007
7-preclinical
Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells.
PMID 17409437·Cancer Res·2007
8-other
Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and nuclear receptor-independent pathways.
PMID 17234778·Cancer Res·2007
7-preclinical
Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists.
PMID 16397256·Cancer Res·2006
7-preclinical
3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha.
PMID 16489053·Cancer Res·2006
7-preclinical
Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells.
PMID 16505105·Mol Cancer Ther·2006
7-preclinical
Vascular endothelial growth factor receptor-2 expression is induced by 17beta-estradiol in ZR-75 breast cancer cells by estrogen receptor alpha/Sp proteins.
PMID 16574784·Endocrinology·2006
8-other
Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins.
PMID 16678129·Biochem Biophys Res Commun·2006
8-other
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
PMID 16788159·J Natl Cancer Inst·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1411 E 31ST ST, 2ND FLR A2
OAKLAND, CA 94602 - Phone
- (510) 437-5039
Quick Facts
- NPI
- 1538693650
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 12
- Publications
- 20
Are you this provider?
Claim Your Profile